Connect Biopharma Reports Significant Revenue Increase and Expanded Clinical Programs in Q2 2026

Connect Biopharma Holdings Limited reported its financial results for the second quarter and first half of 2026, revealing a significant increase in license and collaboration revenues, which reached $2.8 million for the three months ended June 30, 2026, compared to just $48,000 in the same period of 2025. For the first half of 2026, revenues totaled $2.9 million, again a notable rise from the previous year's $48,000. This increase is attributed primarily to the achievement of a regulatory milestone under the company's collaboration agreement with Simcere Pharmaceutical Co., Ltd.

Operating expenses for the second quarter of 2026 were $20.4 million, up from $13.5 million in the same quarter of 2025. This increase was driven largely by a rise in research and development expenses, which surged to $16.3 million from $8.8 million year-over-year, reflecting intensified efforts in the development of the company's lead product candidate, rademikibart. General and administrative expenses decreased slightly to $4.1 million from $4.7 million, primarily due to reduced professional fees. The net loss for the second quarter was $17.3 million, compared to a loss of $12.9 million in the same quarter of the previous year.

In terms of operational developments, Connect Biopharma has made strides in its clinical programs, completing enrollment for the Phase 2 Seabreeze STAT studies evaluating rademikibart for asthma and chronic obstructive pulmonary disease (COPD). The company anticipates topline data from these studies in September 2026, which will inform the design of a potential Phase 3 program. Additionally, the company initiated a new Phase 2 study in August 2026 to evaluate intravenous rademikibart as an add-on treatment for acute exacerbations in patients with asthma or COPD.

As of June 30, 2026, Connect Biopharma had cash, cash equivalents, and short-term investments totaling $31.5 million, which management believes will be sufficient to meet its anticipated cash requirements for at least the next year. The company has incurred significant net losses since its inception and expects to continue doing so for the foreseeable future, relying on equity offerings, collaborations, and other strategic transactions to finance its operations. The company’s employee headcount remained stable, with no significant changes reported in staffing levels.

Looking ahead, Connect Biopharma is focused on advancing its clinical programs and achieving further milestones under its collaboration agreements. The company remains committed to its strategy of developing innovative treatments for respiratory diseases, while navigating the challenges posed by the current macroeconomic environment, including inflation and market volatility.